

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method for treating a bone condition associated with excessive resorption or breakdown of bone tissue, comprising administering to a patient in need thereof FGF-8, or a FGF-8 agonist, wherein the FGF-8 agonist comprises an amino acid sequence at least ~~[[90%]]~~ 95% identical to the amino acid sequence of SEQ ID NO: 1, 2, or 3, ~~or a fragment thereof comprising at least 10 amino acids of the sequence,~~ and wherein FGF-8 or the FGF-8 ~~analog~~ agonist is administered in an amount effective to treat the bone condition in the patient.
2. (Previously presented) The method of claim 1, wherein FGF-8 is administered, and wherein the amino acid sequence of FGF-8 is SEQ ID NO: 1, 2, or 3.
- 3-4. (Canceled)
5. (Currently amended) The method of claim 1, wherein the FGF-8 agonist is administered, and wherein the FGF-8 agonist comprises an amino acid sequence that is at least ~~[[95%]]~~ 98% identical to SEQ ID NO: 1, 2, or 3.
6. (Currently amended) The method of claim 1, wherein the FGF-8 agonist is administered, and wherein the FGF-8 agonist comprises SEQ ID NO: 1, 2, or 3 with up to ~~[[14]]~~ 10 conservative amino acid substitutions.
7. (Currently amended) A method for increasing or maintaining bone density, comprising administering to a subject in need thereof FGF-8, or a FGF-8 agonist, wherein the FGF-8 agonist comprises an amino acid sequence at least ~~[[90%]]~~ 95% identical to the amino acid sequence of

SEQ ID NO: 1, 2, or 3, ~~or a fragment thereof comprising at least 10 amino acids of the sequence,~~
and wherein FGF-8 or the FGF-8 analog agonist is administered in an amount effective to
increase or maintain bone density in the subject.

8. (Previously presented) The method of claim 7, wherein FGF-8 is administered, and wherein
the amino acid sequence of FGF-8 is SEQ ID NO: 1, 2, or 3.

9-10. (Canceled)

11. (Currently amended) The method of claim 7, wherein the FGF-8 agonist is administered,
and wherein the FGF-8 agonist comprises an amino acid sequence that is at least ~~[[95%]]~~ 98%
identical to SEQ ID NO: 1, 2, or 3.

12. (Currently amended) The method of claim 7, wherein the FGF-8 agonist is administered,
and wherein the FGF-8 agonist comprises SEQ ID NO: 1, 2, or 3 with up to ~~[[14]]~~ 10
conservative amino acid substitutions.

13.-18. (Canceled)

19. (Withdrawn) An article of manufacture comprising:

a vessel containing FGF-8, FGF-8 analog, or a FGF-8 agonist; and
written instructions for use of FGF-8, FGF-8 analog, or a FGF-8 agonist for treatment of
a bone condition comprising administering an effective amount of FGF-8, FGF-8 analog, or a
FGF-8 agonist to a patient.

20. (Withdrawn) An article of manufacture comprising:

packaging material; and
contained within the packaging material, FGF-8, FGF-8 analog, or a FGF-8 agonist;
wherein the packaging material comprises a label that indicates that FGF-8, FGF-8 analog, or
a FGF-8 agonist can be used for treating a bone condition in a patient.

21. (Currently amended) A method for treating osteoporosis, osteopenia, bone defects, or osteogenesis imperfecta, comprising:

administration to a subject in need thereof FGF-8, or a FGF-8 agonist, wherein the FGF-8 agonist comprises an amino acid sequence at least ~~[[90%]]~~ 95% identical to the amino acid sequence of SEQ ID NO: 1, 2, or 3, ~~or a fragment thereof, wherein the fragment thereof comprises at least 10 amino acids of the sequence, and~~ wherein FGF-8 or the FGF-8 analog agonist is administered in an amount effective to treat the osteoporosis, osteopenia, bone defects, or osteogenesis imperfecta in the subject.

22. (Withdrawn) A composition comprising FGF-8, FGF-8 analog, or FGF-8 agonist and a pharmaceutically acceptable carrier.

23. (Previously presented) The method of claim 21, wherein FGF-8 is administered, and wherein the amino acid sequence of FGF-8 is SEQ ID NO: 1, 2, or 3.

24-25. (Canceled)

26. (Currently amended) The method of claim 21, wherein the FGF-8 agonist is administered, and wherein the FGF-8 agonist comprises an amino acid sequence that is at least ~~[[95%]]~~ 98% identical to SEQ ID NO: 1, 2, or 3.

27. (Currently amended) The method of claim 21, wherein the FGF-8 agonist is administered, and wherein the FGF-8 agonist comprises SEQ ID NO: 1, 2, or 3 with up to ~~[[14]]~~ 10 conservative amino acid substitutions.